Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s707, 2025. DOI: 10.25251/fpf9fe87. Disponível em: https://skin.dermsquared.com/skin/article/view/3859. Acesso em: 23 jan. 2026.